Committed to developing novel immunotherapies

View More

 

 

About Us

Committed to developing novel immunotherapies

Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.


After 6 years of effort and having made an enormous financial investment, we have constructed 4 major patented technology platforms based on tumor immunotherapy drug R&D: Ori®Ab antibody discovery technology platform, Ori®CAR CAR-T technology platform with high memory and high vitality, Ori®TIL stable and controllable cell culture platform for efficient expansion, and Ori®UCAR general-purpose, convenient and efficient CAR-T technology platform. We have broken through the bottlenecks limiting the efficacy of CAR-T by focusing on target screening, tumor immune microenvironment, T-cell infiltration, and killing ability. We have developed novel drugs with good efficacy, high specificity, and affordable price for tumor immunotherapy, thereby opening up new prospects amidst an explosive development of "novel drugs, made in China".


At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development.

To become the world-leading developer of novel drugs for tumor immunotherapy

Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.

After 6 years of effort and having made an enormous financial investment, we have constructed 4 major patented technology platforms based on tumor immunotherapy drug R&D: Ori®Ab antibody discovery technology platform, Ori®CAR CAR-T technology platform with high memory and high vitality, Ori®TIL stable and controllable cell culture platform for efficient expansion, and Ori®UCAR general-purpose, convenient and efficient CAR-T technology platform. We have broken through the bottlenecks limiting the efficacy of CAR-T by focusing on target screening, tumor immune microenvironment, T-cell infiltration, and killing ability. We have developed novel drugs with good efficacy, high specificity, and affordable price for tumor immunotherapy, thereby opening up new prospects amidst an explosive development of "novel drugs, made in China".

At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development.

Innovative Technology Platforms
  • Ori®Ab
    Antibody discovery technology platform
    A series of high-performance antibodies/CAR-T drug candidates have been developed independently by our company to enhance the synergistic effects between the pipelines.

    The antibody development platform established by our company possesses independent intellectual property rights, which, like a rich mineral deposit, contains large-capacity, diversified 1011 fully-humanized phage display antibody library and the 1010 synthetic nanobody library. This platform can satisfy the development needs of antibodies and CAR T-cell drugs for different indications. A series of high-affinity fully-humanized antibody drug candidate molecules, such as anti-BCMA, GPC-3, PD-L1, IL-17, and 4-1BB antibodies and ScFv- and VH-based CAR-T cells with synergistic effects have been successfully developed.

    There are two major development strategies for our antibody platform. One is to provide targets with a good synergistic effect for CAR-T products, enhancing competitive advantages enjoyed by the company's CAR-T products; the other is to further develop suitable CAR-T targets into antibody drug candidates, so as to yield profits and increase the value of the company through the authorization or cooperative development.

    Ori®Ab
    CAR-T technology platform with high memory and high vitality
    A series of high-performance antibodies/CAR-T drug candidates have been developed independently by our company to enhance the synergistic effects between the pipelines.

    The antibody development platform established by our company possesses independent intellectual property rights, which, like a rich mineral deposit, contains large-capacity, diversified 1011 fully-humanized phage display antibody library and the 1010 synthetic nanobody library. This platform can satisfy the development needs of antibodies and CAR T-cell drugs for different indications. A series of high-affinity fully-humanized antibody drug candidate molecules, such as anti-BCMA, GPC-3, PD-L1, IL-17, and 4-1BB antibodies and ScFv- and VH-based CAR-T cells with synergistic effects have been successfully developed.

    There are two major development strategies for our antibody platform. One is to provide targets with a good synergistic effect for CAR-T products, enhancing competitive advantages enjoyed by the company's CAR-T products; the other is to further develop suitable CAR-T targets into antibody drug candidates, so as to yield profits and increase the value of the company through the authorization or cooperative development.

  • Ori®CAR
    CAR-T technology platform with high memory and high vitality

    We have constructed a novel and exclusively unique signal activation domain element Ori. After being inserted into the Next Generation CAR structure, it can increase the expansion efficiency of memory immune cells by several folds, effectively breaking through the physical barriers of the extracellular matrix in TME, resisting the immunosuppressive tumor microenvironment, significantly enhancing the anti-tumor activity and durability of CAR T-cells in vivo, and preventing recurrence. In addition, low-dose administration is allowed for CAR T-cell therapy involving a high proportion of memory T cells, which further reduces the safety risk caused by the drug itself.

    We have achieved full application of the automated closed-type production process, which effectively reduces the production and preparation costs and improves the affordability of the medications for patients.

    Ori®CAR-T technology platform with high memory and high vitality

    We have constructed a novel and exclusively unique signal activation domain element Ori. After being inserted into the Next Generation CAR structure, it can increase the expansion efficiency of memory immune cells by several folds, effectively breaking through the physical barriers of the extracellular matrix in TME, resisting the immunosuppressive tumor microenvironment, significantly enhancing the anti-tumor activity and durability of CAR T-cells in vivo, and preventing recurrence. In addition, low-dose administration is allowed for CAR T-cell therapy involving a high proportion of memory T cells, which further reduces the safety risk caused by the drug itself.

    We have achieved full application of the automated closed-type production process, which effectively reduces the production and preparation costs and improves the affordability of the medications for patients.

  • Ori®TIL
    Stable and controllable cell culture platform for efficient expansion

    OriCell Therapeutics Ori®TIL: This fast-expansion cell culture technology platform utilizes three major technical tools to break through the bottlenecks, including the difficulty in in vitro TIL expansion, lack of specific tumor residue detection method, and high preparation costs;

    The tumor-killing activity and purity of young TIL cells have been enhanced. The tissue-resident memory T cells (TRM) are strengthened with a shortening of the cell culture cycle, thereby ensuring their effectiveness in clinical use;

    A general-purpose new detection method has been developed to enable detections below the lower limit. The product has definite components and controllable quality of T-cells, thereby ensuring the safety of reinfusion preparations;

    A closed-type production system is utilized, thereby reducing the average preparation costs related to reagent consumables (culture media and cell factors), equipment, personnel, and venues. In this way, we can improve the affordability of clinical treatment.

    Ori®TIL
    Stable and controllable cell culture platform for efficient expansion

    OriCell Therapeutics Ori®TIL: This fast-expansion cell culture technology platform utilizes three major technical tools to break through the bottlenecks, including the difficulty in in vitro TIL expansion, lack of specific tumor residue detection method, and high preparation costs;

    The tumor-killing activity and purity of young TIL cells have been enhanced. The tissue-resident memory T cells (TRM) are strengthened with a shortening of the cell culture cycle, thereby ensuring their effectiveness in clinical use;

    A general-purpose new detection method has been developed to enable detections below the lower limit. The product has definite components and controllable quality of T-cells, thereby ensuring the safety of reinfusion preparations;

    A closed-type production system is utilized, thereby reducing the average preparation costs related to reagent consumables (culture media and cell factors), equipment, personnel, and venues. In this way, we can improve the affordability of clinical treatment.

  • Ori®UCAR
    General-purpose, convenient and efficient CAR-T technology platform

    The platform uses gene editing technology with efficient coordination of several advantageous platforms, including Ori®Ab, Ori®CAR, and cell expansion and culture. Thus high versatility and convenience of UCAR products can be achieved in the future using the platform, thereby reducing the economic burden for patients.

    The cells come from allogeneic healthy donors, and a self-owned GMP-level iPS cell bank has been built using denoted cells. Off-the-shelf: With no need for cross-matching or waiting for long. The patients can receive multiple injections to further enhance the efficacy. It can successfully prevent immunological rejection. Besides, the expansion and differentiation potentials of gene-edited iPS cells are not affected by multiple editing. Moreover, the cells thus produced have a high editing rate, high specificity, and strong tumor cell killing activity. This platform is suitable for standardized and large-scale production and has achieved a considerable reduction in manufacturing costs.

    Ori®UCAR
    General-purpose, convenient and efficient CAR-T technology platform

    The platform uses gene editing technology with efficient coordination of several advantageous platforms, including Ori®Ab, Ori®CAR, and cell expansion and culture. Thus high versatility and convenience of UCAR products can be achieved in the future using the platform, thereby reducing the economic burden for patients.

    The cells come from allogeneic healthy donors, and a self-owned GMP-level iPS cell bank has been built using denoted cells. Off-the-shelf: With no need for cross-matching or waiting for long. The patients can receive multiple injections to further enhance the efficacy. It can successfully prevent immunological rejection. Besides, the expansion and differentiation potentials of gene-edited iPS cells are not affected by multiple editing. Moreover, the cells thus produced have a high editing rate, high specificity, and strong tumor cell killing activity. This platform is suitable for standardized and large-scale production and has achieved a considerable reduction in manufacturing costs.

Investors
  • SPINNOTEC

    View
  • Zhangjiang Technology Venture Capital

    View
  • C&D Emerging Industry Equity Investment

    View
  • Origincell

    View
  • Qiming Venture Partners

    View
  • Yijing Capital

    View

SPINNOTEC

SPINNOTEC is a large-scale state-owned conglomerate invested and founded by the government of Pudong New District of Shanghai to boost the construction of a globally influential scientific innovation center and the growth of high-tech industries. It is mainly engaged in venture capital investment and technology financial services. Founded in June 1999, the company is one of China's first state-owned venture capital institutions supported by local governments. SPINNOTEC focuses on "hard and core technology," and has invested in over 800 companies (over 150 of which have been successfully listed or exited through mergers and acquisitions, and 14 of which have been listed on the science and technology innovation board) and more than 50 venture capital funds, with a total fund scale of more than 100 billion yuan. It has supported high-tech companies 1500 times by providing tens of billion yuan of loans and financial guarantee services; it has been rated as "China's Top 10 Government-Led Funds" and an outstanding investment institution for many years. SPINNOTEC is currently enjoying a very good reputation in the industry.

Zhangjiang Technology Venture Capital

Shanghai Zhangjiang Technology Venture Capital Co., Ltd. (hereafter referred to as "Zhangjiang Technology Venture Capital"), founded in October 2004, is a wholly-owned subsidiary of Shanghai Zhangjiang (Group) Co., Ltd. At the end of 2014, through resources integration, Zhangjiang Technology Venture Capital released a technological innovation service platform that combines investment, loans, incubation, and education. Zhangjiang Technology Venture Capital adopts the strategic positioning as "a promoter of emerging industries and a builder of technological innovation ecosystem". It has built a whole-value-chain technological innovation service ecosystem that supports the growth of entrepreneurs and promotes the agglomeration of technological innovation industries. Zhangjiang Technology Venture Capital has been focusing on leading industries such as digital information and life health and has put enormous efforts into the cultivation of these fields over the years. It pays close attention to such industry hotspots as the intelligence of technologies, consumption upgrading, innovative drugs, and the integration of artificial intelligence into medical technology. Zhangjiang Technology Venture Capital supports the development of entrepreneurial projects with technological and team advantages and also shares their growth gains.

C&D Emerging Industry Equity Investment

C&D Emerging Industry Equity Investment is an enterprise-level venture capital institution supported by the C&D Group, a Fortune 500 enterprise. Founded in 2014, the company carries out the mission of "exploring new values and helping more growth-type new-economy enterprises achieve better development". C&D Emerging Industry Equity Investment focuses on new economy sectors such as healthcare, advanced manufacturing, and TMT/consumption.

Origincell

Origincell is the founding shareholder of Origincell Therapeutics, which was jointly established in 2014 by Canature Health (300272), a GEM-listed company, and its founder, Mr. Qu Jianguo. With a first-phase investment of 1.5 billion yuan, Origincell has built three industrial parks covering an area of 80 acres and having a construction area of nearly 100,000 square meters in the core zone of Zhangjiang Science City. These three industrial parks have also attracted many other biomedical innovation enterprises with great potentials. Origincell also owns the following subsidiaries: Origincell Biological Cryo Equipment Co., Ltd., specialized in R&D and production of cell cryopreservation equipment; Yuantian Biotechnology Co., Ltd., specialized in stem cell and exosome research and cell preparation and culture services; Origincell-Bank Co., Ltd., specialized in automated and intelligent cell preservation services. These subsidiaries constitute a complete industrial chain. The total number of patents applied by the Origincell has exceeded 300, which indicates stable development and bright prospects. 

Qiming Venture Partners

Qiming Venture Partners, founded in 2006, is currently managing 7 phases of USD funds and 5 phases of RMB funds. The total assets under its management are more than 4 billion USD. Qiming Venture Partners focuses on investing in exceptional firms in the TMT and Healthcare fields at the start-up and growth stages. Since its founding, Qiming Venture Partners has been highly acknowledged for its outstanding investment performance by investors from China and all over the world and has become a top-choice investment institution for entrepreneurs. Qiming Venture Partners has risen to the top in many reputable rankings of China's venture capital business. It has collaborated with many excellent high-tech entrepreneurs to create unicorn and listed enterprises.

Yijing Capital

Yijing Capital, founded in 2015, is mainly engaged in primary market equity investment and fund of funds (FOF) investment using its own funds and privately offered funds. Adhering to the concept of "helping enterprises innovate and grow, promoting industrial optimization and upgrading, and boosting social development and progress", Yijing Capital focuses on areas including big health industry, TMT & big consumption, and hard and core technology. It is specialized in investing in high-value high-tech innovative enterprises at their start-up and growth stages. As to the medical field, Yijing Capital has invested in many industry-leading enterprises, including Leto Laboratories, Our United Corp., Hanyu Medical, SS Innovations, WELLEM Pediatrics, and MedSci.

Clinical Center

We have established a strategic partnership with a number of grade-A tertiary hospitals to accelerate clinical medicine transformation

  • Zhongshan Hospital
  • Renji Hospital
  • Changzheng Hospital
  • Shanghai General Hospital
  • The First Affiliated Hospital of Zhejiang University School of Medicine
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
  • Lishui Central Hospital